Abstract | BACKGROUND: METHODS: The study recruits patients diagnosed with a variety of psychiatric disorders and has a longitudinal cohort design with an assessment at baseline and at one-year follow-up. The primary outcome measure is cognitive functioning. The secondary outcome measures include clinical symptoms, electroencephalographic, genetic and blood markers (e.g., fatty acids), and hair cortisol concentration levels. DISCUSSION: The Across study provides an opportunity for a transdiagnostic, bottom-up, data-driven approach of investigating cognition in relation to symptoms and biological parameters longitudinally in patients with psychiatric disorders. The study may help to find new clusters of symptoms, biological markers, and cognitive dysfunctions that have better prognostic value than the current diagnostic categories. Furthermore, increased insight into the relationship among cognitive deficits, biological parameters, and psychiatric symptoms can lead to new treatment possibilities. TRIAL REGISTRATION: Netherlands Trial Register (NTR): NL8170.
|
Authors | Dorien H Nieman, UnYoung Chavez-Baldini, Nienke C Vulink, Dirk J A Smit, Guido van Wingen, Pelle de Koning, Arjen L Sutterland, Roel J T Mocking, Claudi Bockting, Karin J H Verweij, Anja Lok, Damiaan Denys |
Journal | BMC psychiatry
(BMC Psychiatry)
Vol. 20
Issue 1
Pg. 212
(05 11 2020)
ISSN: 1471-244X [Electronic] England |
PMID | 32393362
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Topics |
- Clinical Protocols
- Cognition
(physiology)
- Depressive Disorder, Major
(blood, diagnosis)
- Humans
- Netherlands
- Schizophrenia
(blood, diagnosis)
|